Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label, Single-Arm Study to Evaluate the Safety, Immunogenicity Reduction, Transplant Function, and Feasibility of Ex Vivo CRISPR-Cas9 Gene-Edited Donor Liver Transplantation Targeting HLA Class I (HLA-A, HLA-B) and Class II (Via CIITA) Genes.

NCT07053488 is registered in ClinicalTrials.gov with AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC as lead sponsor.

NCT NCT07053488
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07053488 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label, Single-Arm Study to Evaluate the Safety, Immunogenicity Reduction, Transplant Function, and Feasibility of Ex Vivo CRISPR-Cas9 Gene-Edited Donor Liver Transplantation Targeting HLA Class I (HLA-A, HLA-B) and Class II (Via CIITA) Genes.
Lead sponsor
AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 1, 2025
Completion date
December 28, 2028
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liver cancer, liver cirrhosis, liver diseases, liver failure, liver metastases, liver steatoses, liver transplant rejection